Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) provided updates and financial results for Q3 2021. The company is progressing its anti-integrin mAb program targeting solid tumors, with first patient dosing expected in H1 2023. Lenabasum's Phase 2 study data is anticipated in Q4 2021. Revenue decreased to approximately $97,000 from $1.23 million in 2020, while operating expenses fell to $14 million from $35.2 million due to reduced clinical costs. Corbus reported a net loss of $2.2 million, down significantly from $34.9 million year-over-year. The company holds $108 million in cash, funding operations into Q1 2024.
- Significant reduction in operating expenses from $35.2 million to $14 million.
- Net loss decreased substantially from $34.9 million to $2.2 million.
- Strong cash position with $108 million to support operations through Q1 2024.
- Advancements in anti-integrin mAb and cannabinoid receptor programs.
- Revenue declined significantly from $1.23 million to $97,000.
- Ongoing losses indicate financial pressure despite reduced expenses.
NORWOOD, Mass., Nov. 12, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided corporate updates and reported financial results for the third quarter of 2021.
Key Programs' Updates:
- Anti-integrin monoclonal antibody (mAb) program targeting solid tumors continues to advance toward the clinic with first patient dosed anticipated in first half of 2023 following filing of an IND. The solid tumor program is focused on inhibiting αvβ8-activation of diffusible and non-diffusible TGFβ, a multifunctional cytokine which mediates immune evasion and plays a key role in promoting cancer growth and metastasis via its immunosuppressive effects in the tumor microenvironment (TME).
- Lenabasum: Topline data from the National Institutes of Health-sponsored Phase 2 study of lenabasum in systemic lupus erythematosus is on track and expected in Q4 2021. The Company is also working on gaining clarity from the FDA on the potential path forward in the dermatomyositis program.
- Cannabinoid receptor type 1 (CB1) small molecule program is progressing through preclinical studies and regulatory pathway evaluation. Corbus' CB1 inverse agonists are in development for treatment of obesity and related metabolic diseases. In animal models of diet-induced obesity, Corbus compounds induce weight loss both as a monotherapy and in combination with a GLP-1 agonist.
Yuval Cohen, Ph.D., Chief Executive Officer said, "The third quarter was productive for Corbus as we advanced our lead programs toward the clinic. It is exciting to see the developments in integrin biology and begin to appreciate the potential impact of our program. We have the operating capabilities in place and are in a strong financial position to execute our strategy to progress our diversified pipeline."
The Company is continuing to explore development pathways for its cannabinoid receptor type 2 (CB2) program targeting cancer and anti-integrin mAb program targeting fibrosis.
Financial Results for First Quarter Ended September 30, 2021:
Revenue from awards and licenses was approximately
Operating expenses decreased by
The Company reported a net loss of approximately
As of September 30, 2021, the company has
About Corbus
Corbus is committed to connecting innovation to our purpose of improving lives by developing new medicines that target inflammation, fibrosis, metabolism and immuno-oncology, by building upon our underlying expertise in immunology. Corbus' current pipeline includes small molecules that activate or inhibit the endocannabinoid system and anti-integrin monoclonal antibodies that block activation of TGFβ. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Corbus Pharmaceuticals Contacts:
Lindsey Smith, Director, Investor Relations and Corporate Communications
Phone: +1 (617) 415-7749
Investors: ir@corbuspharma.com
Media: mediainfo@corbuspharma.com
Corbus Pharmaceuticals Holdings, Inc. | ||||||||
Condensed Consolidated Balance Sheets | ||||||||
September 30, 2021 | December 31, 2020 | |||||||
(Unaudited) | ||||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 37,118,654 | $ | 85,433,441 | ||||
Marketable securities | 69,744,151 | — | ||||||
Restricted cash | 192,475 | 350,000 | ||||||
Stock subscriptions receivable | — | 960,033 | ||||||
Prepaid expenses and other current assets | 2,111,858 | 3,712,861 | ||||||
Contract asset | 2,500,000 | 1,618,296 | ||||||
Total current assets | 111,667,138 | 92,074,631 | ||||||
Restricted cash | 477,425 | 669,900 | ||||||
Property and equipment, net | 2,652,828 | 4,067,837 | ||||||
Operating lease right of use assets | 4,776,571 | 5,248,525 | ||||||
Other assets | — | 234,038 | ||||||
Total assets | $ | 119,573,962 | $ | 102,294,931 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Notes payable | $ | — | $ | 710,158 | ||||
Accounts payable | 2,545,919 | 7,381,183 | ||||||
Accrued expenses | 13,368,133 | 22,005,432 | ||||||
Derivative liability | 126,857 | 797,000 | ||||||
Operating lease liabilities, current | 1,102,727 | 1,004,063 | ||||||
Total current liabilities | $ | 17,143,636 | 31,897,836 | |||||
Long-term debt, net of debt discount | 18,550,502 | 18,029,005 | ||||||
Operating lease liabilities, noncurrent | 6,251,038 | 7,093,165 | ||||||
Total liabilities | $ | 41,945,176 | 57,020,006 | |||||
Stockholders' equity | ||||||||
Preferred stock, | — | — | ||||||
Common stock, | 12,523 | 9,885 | ||||||
Additional paid-in capital | 417,098,261 | 349,358,378 | ||||||
Accumulated deficit | (339,473,031) | (304,093,338) | ||||||
Accumulated other comprehensive loss | (8,967) | — | ||||||
Total stockholders' equity | 77,628,786 | 45,274,925 | ||||||
Total liabilities and stockholders' equity | $ | 119,573,962 | $ | 102,294,931 | ||||
Corbus Pharmaceuticals Holdings, Inc. | ||||||||||||||||
Condensed Consolidated Statements of Operations | ||||||||||||||||
(Unaudited) | ||||||||||||||||
For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Revenue from awards and licenses | $ | 97,323 | $ | 1,230,621 | $ | 881,705 | $ | 3,279,026 | ||||||||
Operating expenses: | ||||||||||||||||
Research and development | 8,695,641 | 27,522,989 | 30,681,684 | 82,156,926 | ||||||||||||
General and administrative | 5,277,090 | 7,681,573 | 16,190,684 | 23,120,020 | ||||||||||||
Total operating expenses | 13,972,731 | 35,204,562 | 46,872,368 | 105,276,946 | ||||||||||||
Operating loss | (13,875,408) | (33,973,941) | (45,990,663) | (101,997,920) | ||||||||||||
Other income (expense), net: | ||||||||||||||||
Other income (expense), net | 12,033,031 | (4,972) | 11,790,328 | 4,005 | ||||||||||||
Interest income (expense), net | (391,867) | (454,319) | (1,439,587) | (348,654) | ||||||||||||
Change in fair value of derivative liability | 472,143 | (211,000) | 670,143 | (211,000) | ||||||||||||
Foreign currency exchange gain (loss), net | (414,048) | (251,117) | (409,914) | (103,903) | ||||||||||||
Other income (expense), net | 11,699,259 | (921,408) | 10,610,970 | (659,552) | ||||||||||||
Net loss | $ | (2,176,149) | $ | (34,895,349) | $ | (35,379,693) | $ | (102,657,472) | ||||||||
Net loss per share, basic and diluted | $ | (0.02) | $ | (0.43) | $ | (0.29) | $ | (1.37) | ||||||||
Weighted average number of common shares outstanding, basic and diluted | 125,209,985 | 81,879,119 | 122,234,847 | 75,037,418 | ||||||||||||
Comprehensive loss: | ||||||||||||||||
Net loss | $ | (2,176,149) | $ | (34,895,349) | $ | (35,379,693) | $ | (102,657,472) | ||||||||
Other comprehensive income (loss): | ||||||||||||||||
Unrealized gain (loss) on marketable debt securities | (3,513) | — | (8,967) | — | ||||||||||||
Total other comprehensive income (loss) | (3,513) | — | (8,967) | — | ||||||||||||
Total comprehensive loss | $ | (2,179,662) | $ | (34,895,349) | $ | (35,388,660) | $ | (102,657,472) | ||||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/corbus-pharmaceuticals-reports-third-quarter-2021-financial-results-and-provides-corporate-updates-301422218.html
SOURCE Corbus Pharmaceuticals Holdings, Inc.
FAQ
What were the financial results for Corbus Pharmaceuticals in Q3 2021?
What is the status of Corbus Pharmaceuticals' anti-integrin mAb program?
How much cash does Corbus Pharmaceuticals have for operations?
When is the topline data for lenabasum expected?
How have operating expenses changed for Corbus Pharmaceuticals?
